Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart...
The FDA has granted Priority Review to Arexvy for the prevention of RSV disease in adults aged 50 to 59 years who are at increased risk for RSV disease.
Life Sciences Stock News Bite - Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
The approval provides patients with the first-ever treatment option for severe frostbite to prevent the amputation of fingers or toes.
The FDA has granted Priority Review to Arexvy for the prevention of RSV disease in adults aged 50 to 59 years who are at increased risk for RSV disease.